

Vancheswaran Gopalakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6560632/publications.pdf>

Version: 2024-02-01

46
papers

14,545
citations

236925

25
h-index

265206

42
g-index

50
all docs

50
docs citations

50
times ranked

19474
citing authors

#	ARTICLE	IF	CITATIONS
1	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). <i>Neoplasia</i> , 2022, 31, 100813.	5.3	14
2	Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen. <i>Microorganisms</i> , 2021, 9, 1399.	3.6	12
3	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
4	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
5	Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. <i>Clinical Infectious Diseases</i> , 2020, 71, 63-71.	5.8	61
6	Antibiotics and Immunotherapy: Too Much of Anything is Bad!. <i>European Urology</i> , 2020, 78, 544-545.	1.9	2
7	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.3	8
8	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. <i>Science</i> , 2020, 368, 973-980.	12.6	1,077
9	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
10	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	12.0	160
11	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1025-1035.	3.4	70
12	The microbiome, cancer, and cancer therapy. <i>Nature Medicine</i> , 2019, 25, 377-388.	30.7	712
13	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. <i>Cancer Cell</i> , 2018, 33, 570-580.	16.8	911
14	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	27.6	389
15	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	10.7	233
16	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
17	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	30.7	521
18	Implicating or exonerating the gut microbiome in blood-borne infection. <i>Nature Medicine</i> , 2018, 24, 1788-1789.	30.7	3

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
20	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
21	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. <i>Trends in Immunology</i> , 2018, 39, 900-920.	6.8	56
22	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 946.	4.8	19
23	Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks. <i>Frontiers in Microbiology</i> , 2018, 9, 297.	3.5	19
24	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
25	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	4.1	24
26	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
27	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	12.6	1,059
28	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
29	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	3.7	20
30	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncot Immunology</i> , 2017, 6, e1321187.	4.6	45
31	Synovial Sarcoma of the Head and Neck: A Single Institution Review. <i>Sarcoma</i> , 2017, 2017, 1-8.	1.3	27
32	Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. , 2017, , .		4
33	Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3008-3008.	1.6	23
34	Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9575-9575.	1.6	1
35	Prognosis of T1 synovial sarcoma depends upon surgery by oncologic surgeons. <i>Journal of Surgical Oncology</i> , 2016, 114, 490-494.	1.7	11
36	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785

#	ARTICLE	IF	CITATIONS
37	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	4.6	55
38	Head and neck synovial sarcomas: Clinical characteristics and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22523-e22523.	1.6	0
39	Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy. , 2016, , .		0
40	Working with Human Tissues for Translational Cancer Research. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	2
41	Mitochondrial DNA Copy Number in Peripheral Blood and Melanoma Risk. <i>PLoS ONE</i> , 2015, 10, e0131649.	2.5	29
42	Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. <i>Sarcoma</i> , 2014, 2014, 1-6.	1.3	27
43	Survival of upper tract urothelial carcinoma: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 257-257.	1.6	1
44	Are adult and pediatric neuroblastoma clinically different entities?. <i>Journal of Clinical Oncology</i> , 2013, 31, 10049-10049.	1.6	0
45	A rapid method to estimate the value of genetic analysis of excised cancers: A comparison in the phase I setting.. <i>Journal of Clinical Oncology</i> , 2013, 31, 264-264.	1.6	0
46	The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3